trandolapril / Generic mfg. - LARVOL DELTA

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study (clinicaltrials.gov) - P=N/A | N=13656 | Not yet recruiting | Sponsor: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

New trial • Real-world evidence • Cardiovascular • Infectious Disease • Pneumonia • Respiratory Diseases

Trandolapril Attenuates Pro-Arrhythmic Downregulation of Cx43 and Cx40 in Atria of Volume Overloaded Hypertensive and Normotensive Rats. (PubMed, Biomolecules) - "We investigated the impact of volume overload on Cx43 and Cx40 in right and left heart atria of hypertensive pressure overloaded Ren-2 transgenic (TGR) strain and normotensive Hannover Sprague Dawley (HSD) rats, as well as the efficacy of renin-angiotensin blockade with trandolapril and losartan. Trandolapril attenuated pro-arrhythmic downregulation of Cx43 and Cx40 in atria of volume overloaded normotensive as well as hypertensive rats. This fact as well as examining AF inducibility requires further investigation."

Journal • Preclinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Nephrology • Renal Disease

A soluble guanylate cyclase stimulator improves survival in a rat model of heart failure with reduced ejection fraction and chronic kidney disease induced by aorto-caval fistula and 5/6 nephrectomy (ESC-WCC 2025) - "One week later, ACF was created; another two weeks later, the animals were randomly divided into three groups, and the therapy was started: sGC stimulation with BAY-41-8543 (sGC stim.) (3 mg.kg-1.day-1 in food, n = 24), angiotensin-converting enzyme inhibitor (ACEi) (trandolapril, 2 mg.L-1 in drinking water, n = 24), or placebo (n = 22)...Conclusion(s) Our results indicate that in the ACF-5/6Nx TGR animal model of combined HF and CKD, treatment with an sGC stimulator reduces mortality to a similar extent as ACEi monotherapy compared to placebo. Further preclinical research is needed to better understand the NO/sGC/cGMP pathway in HF with concurrent CKD."

Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Trandolapril mitigates heart connexin43 and ECM disorders in dual pressure and volume overload heart failure (ESC-WCC 2025) - "There is a benefit of treatment with trandolapril and losartan, indicating their pleiotropic anti-arrhythmic potential. This may provide novel insights into medical therapy for HF and arrhythmias."

Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • MMP2 • SMAD2

Molecular basis of domain-specific angiotensin I-converting enzyme inhibition by the antihypertensive drugs enalaprilat, ramiprilat, trandolaprilat, quinaprilat and perindoprilat. (PubMed, FEBS J) - "None of the binding modes of the inhibitors extend beyond the S1-S2' subsites to make use of the unique nACE/cACE residues that have been shown to influence domain selectivity. These findings supplement our understanding of ACE inhibition by the clinically used ACE inhibitors, and this information should be useful in the future design of more domain-selective inhibitors for the treatment of hypertension and cardiovascular diseases."

Journal • Cardiovascular • Fibrosis • Hypertension • Immunology

Dehydration and hypertension differently prime intrinsic and pre-renal AKI (ERA 2025) - "- Pre-renal AKI: induced by triple whammy therapy (concomitant treatment with oral doses of 0.7 mg/kg/day trandolapril, i.p. doses of 60 mg/kg/day ibuprofen, and of 20 mg/kg/day furosemide) for two consecutive days. Dehydration differently primes intrinsic and pre-renal AKI under normotension and hypertension. Thus, in normotensive animals, dehydration constitutes an important risk factor for pre-renal AKI induced by TW but not for intrinsic AKI induced by cisplatin, where loss of hydration status did not aggravate renal dysfunction observed after cisplatin treatment. However, in hypertensive animals, whereas dehydration sensitize them to intrinsic AKI caused by cisplatin, it does not constitute a risk factor for TW-induced pre-renal AKI unless sustained over the time."

Acute Kidney Injury • Cardiovascular • Hypertension • Nephrology • Renal Disease

Effect of increasing age on pre-renal AKI incidence and severity in dehydrated and normohydrated rats (ERA 2025) - " Two- and thirteen-month-old male Wistar rats were divided into three experimental groups: TW group: with free access to water during the whole experiment receiving TW therapy for two days (oral doses of 0.7 mg/kg/day trandolapril, i.p. doses of 60 mg/kg/day ibuprofen, and of 20 mg/kg/day furosemide). These results suggest that age increases the susceptibility to AKI under dehydration and TW use, and that younger rats show variability in renal homeostasis efficiency across individuals."

Preclinical • Acute Kidney Injury • Nephrology • Renal Disease

Trandolapril attenuates renal fibrosis in rats with a dual-injury model of kidney disease progression. (ERA 2025) - " We developed a transition model from acute kidney injury (AKI) to CKD, where the acute phase of the disease is induced through the administration of a nephrotoxic single dose of cisplatin (5 mg/kg). Our study provides evidence that trandolapril can mitigate the development of renal fibrosis in a rat model transitioning from AKI to CKD. This beneficial effect, observed despite the absence of hemodinamic and kidney function changes, highlights the potential of ACE inhibitors to prevent long-term structural damage and may have important implications for the management of patients at risk for CKD progression after AKI episodes."

Preclinical • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • Reperfusion Injury

Comparison chart: Some drugs for HFrEF. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Drugs for chronic heart failure. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Ramipril, perindopril and trandolapril as potential chemosensitizers in ovarian cancer: considerations for drug repurposing. (PubMed, Drug Discov Today) - "Moreover, clinical data have shown that using ACE-Is with standard chemotherapy prolongs patient survival. Based on this rationale, we discuss the available in vitro models of OC for future studies with ACE-Is and demonstrate an in silico approach that has enabled us to select the most promising molecules: perindopril, ramipril, trandolapril and their diketopiperazine derivatives."

Journal • Review • Oncology • Ovarian Cancer • Solid Tumor

Amlodipine-Associated Angioedema: An Integrated Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis and Case Reviews. (PubMed, J Clin Med) - "Significant safety signals were detected for amlodipine alone and in combination with aliskiren, specific ACE inhibitors (quinapril, benazepril, trandolapril, fosinopril, perindopril), and certain ARBs (candesartan, losartan). While these results should not discourage appropriate clinical use, they emphasize the importance of monitoring for angioedema, particularly during therapy initiation. The findings from this study need to be validated in prospective studies for further elucidation of the underlying mechanisms."

Adverse events • Journal • Cardiovascular • Hypertension

Effect of Sacubitril/valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: a Real World Study (clinicaltrials.gov) - P=N/A | N=180 | Recruiting | Sponsor: Beijing Friendship Hospital | Trial completion date: Sep 2024 ➔ Jun 2027 | Trial primary completion date: Mar 2024 ➔ Dec 2026

Real-world evidence • Trial completion date • Trial primary completion date • Cardiovascular • Genetic Disorders • Hypertension • Obesity

Hypertensive Encephalopathy Triggered by Indomethacin Use. (PubMed, Clin Case Rep) - "However, his headaches were in the context of worsening hypertension that was treated with trandolapril. NSAID use can trigger blood pressure decompensation, especially in patients with underlying hypertension; this effect is particularly pronounced in patients treated with anti-hypertensive medications that inhibit the renin-angiotensin-aldosterone (RAS) system. Symptomatic treatment with NSAIDs is not without potential harm; it is important to carefully consider a patient's underlying diagnosis, indication for therapy and risk for adverse effects."

Journal • Cardiovascular • CNS Disorders • Hypertension • Pain

Modulation of left ventricular hypertrophy in spontaneously hypertensive rats by acetylcholinesterase and ACE inhibitors: physiological, biochemical, and proteomic studies. (PubMed, Front Cardiovasc Med) - "Here, the efficacy of pyridostigmine (PYR) and trandolapril (TRA) as antihypertensive and antihypertrophic agents was investigated and compared in hypertensive SHR and normotensive WKY rats...PYR is able to slightly decrease BP and HR in SHR rats but effectively increase BRS through vagal potentiation. The specific differences in protein expression profiles in rat myocardium induced by treatment with PYR and TRA reflect different mechanisms of action of these two agents at the molecular level."

Journal • Preclinical • Cardiovascular • Hypertension

Development of triple-whammy induced pre-renal AKI is highly dependent on the hydration status (ERA-EDTA 2024) - " Two-month-old male Wistar rats were divided into 3 experimental groups: -TW group: rats with free access to drinking water during the whole experiment receiving TW therapy for two days (oral doses of 0.7 mg/kg/day trandolapril, i.p. doses of 60 mg/kg/day ibuprofen, and of 20 mg/kg/day furosemide). TW-induced AKI in young Wistar rats is facilitated when the hydration status worsens. In this sense, assessing hydration and implementing (re)hydration strategies may help to reduce or prevent TW-induced AKI."

Acute Kidney Injury • Nephrology

DEHYDRATION CANNOT SUBSTITUTE FOR ANY OF THE TRIPLE WHAMMY DRUGS TO CAUSE ACUTE KIDNEY INJURY. (ERA-EDTA 2024) - " Three months old male Spontaneously Hypertensive Rats (SHR) were divided into four experimental groups: control group (CT); TW group (TW), which received four days of double therapy with trandolapril and furosemide, followed by a triple therapy for two days with trandolapril, furosemide and ibuprofen; trandolapril and ibuprofen group (T+I), which received four days of trandolapril followed by two days of trandolapril and ibuprofen; furosemide and ibuprofen group (F+I), which received four days of furosemide followed by two days of furosemide and ibuprofen; and trandolapril and furosemide group (T+F), which received six days of trandolapril and furosemide. In our in vivo model of TW-AKI, mild dehydration cannot replace any of the TW drugs, although it appears that combination of F+I and T+F in dehydrated rats slightly alter plasma urea and creatinine clearance values at day 6, suggesting that this condition maintained over time might lead to the development of AKI."

Acute Kidney Injury • Cardiovascular • Hypertension • Nephrology • Renal Disease

Drugs for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Review • Cardiovascular • Hypertension

ADAMTS13 deficiency exacerbates neuroinflammation by targeting matrix metalloproteinase-9 in ischemic brain injury. (PubMed, Neuroreport) - "MMP-9 downregulation was achieved by using ACE inhibitors such as trandolapril...It showed that ADAMTS13 deficiency exacerbated ischemic brain injury through an MMP-9-dependent inflammatory mechanism. Therefore, the ADAMTS13-MMP-9 axis could have therapeutic potential for the treatment of AIS."

Journal • Cardiovascular • CNS Disorders • Inflammation • Ischemic stroke • Vascular Neurology • MMP9

Angiotensin II Is Involved in MLKL Activation During the Development of Heart Failure Following Myocardial Infarction in Rats. (PubMed, Biol Pharm Bull) - "We found that administration of azilsartan, an angiotensin II AT1 receptor blocker, or trandolapril, an angiotensin-converting enzyme inhibitor, to rats from the 2nd to the 8th week after myocardial infarction resulted in preservation of cardiac function and attenuation of mixed lineage kinase domain-like (MLKL) activation. Pretreatment with azilsartan also prevented the conditioned medium-induced increase in activated MLKL. These results suggest that angiotensin II contributes to the induction of myocardial necroptosis during the development of heart failure."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=20000 | Recruiting | Sponsor: UMC Utrecht | N=10000 ➔ 20000

Enrollment change • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

The impact of phosphodiesterase-5 inhibition or angiotensin-converting enzyme inhibition on right and left ventricular remodeling in heart failure due to chronic volume overload. (PubMed, Pharmacol Res Perspect) - "ACF animals were randomized for PDE5i sildenafil, ACEi trandolapril, or placebo treatments. PDE5i did not improve survival rate and cardiac and renal function in ACF rats, in contrast to ACEi. VO-induced HF is not responsive to PDE5i therapy."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Renal Disease

MELANOMA AND DYSPLASTIC NEVI DEVELOPMENT AFTER RANITIDINE/RILMENIDINE/МOXONIDINE, LERCANIDIPINE, ROSUVASTATIN AND VERAPAMIL/TRANDOLAPRIL - NEW DATA/CASE SERIES. THE POTENTIAL ROLE OF NITROSAMINE/NDSRIS CONTAMINATION IN POLYMEDICATION AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR. (PubMed, Georgian Med News) - "In the last decade, melanoma has been described repeatedly in the medical literature as a possible side-effect within the intake of possibly with nitrosamines contaminated medications such as: Valsartan, Hydrochlorothiazide, Amlodipine, Nebivolol, Bisoprolol and Perindopril. Ingredients that are present in drug preparations, identified as availability and as carcinogenic potency, but not yet reflected in packaging or prescriptions. The question remains: why?"

Journal • Cutaneous Melanoma • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor

The association between ACE inhibitors and psoriasis based on the drug-targeted Mendelian randomization and real-world pharmacovigilance analyses. (PubMed, Expert Rev Clin Pharmacol) - "Furthermore, our disproportionality analysis revealed that ramipril, trandolapril, perindopril, lisinopril, and enalapril were associated with the risk of psoriasis, which validates and refines the findings of the DTMR. Our integrative study verified that ACEIs, especially ramipril, trandolapril, perindopril, lisinopril, and enalapril, tended to increase the risk of psoriasis statistically."

Adverse events • Journal • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

The treatment with trandolapril and losartan attenuates pressure and volume overload alternations of cardiac connexin-43 and extracellular matrix in Ren-2 transgenic rats. (PubMed, Sci Rep) - "There is benefit of treatment with trandolapril and losartan indicating their pleiotropic anti-arrhythmic potential. It may provide novel input to therapy."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • MMP2 • SMAD2